YAP1 and mesothelioma: In human xenograft mouse models, oral IAG933 treatment led to tumor regression at tolerable doses in mesothelioma (143). A comparison to VT104 and K-975 showed that IAG933 had a more potent effect on YAP/TAZ-TEAD target gene expression, but had a shorter half life in the blood and tumor than VT104 (143).